BioSpace News Archive

Words IPO (Initial public offering) with the trading data on the background.

IPO

2026 IPO stock tracker: How newly public biotechs are performing

BioSpace is launching an IPO dashboard to help the industry keep tabs on U.S. biotechs that have taken the public plunge in 2026.

October 19, 2026

·

1 min read

·

Gabrielle Masson

Sponsored by Sino Biological

From cells to organoids: Cytokines that shape 3D culture

High-quality cytokines for organoid growth, differentiation, and expansion.

October 19, 2026

·

7 min read

·

Mengtong Cao, Ph.D.

Cityscape of Madrid’s financial district at dusk, featuring modern skyscrapers illuminated against the fading evening sky. This area on the North of the city stands out as a symbol of contemporary architecture and economic dynamism in the Spanish capital, blending urban sophistication with a tranquil twilight ambiance.

cancer

Merck/Moderna, Summit/Akeso and ADCs to headline ESMO 2026

At the European Society of Medical Oncology meeting in Madrid this weekend, analysts will be watching for detailed data on Merck and Moderna’s personalized cancer vaccine, Summit and Akeso’s PD-1xVEGF bispecific therapy, and a host of antibody-drug conjugates.

October 19, 2026

·

8 min read

·

Tristan Manalac

Creative collage human 3d hands body fragments needle injection gloves medical healthcare hospital virus prevention drawing background.

Insights

More arms, more questions: The new challenge in multispecific drug design

As trispecifics, cell engagers and other complex formats multiply, drug developers are seeking discovery and engineering partners to help navigate an expanding universe of molecular possibilities.

October 19, 2026

·

5 min read

·

Jennifer C. Smith-Parker

Two Closed Doors with Different Color in Front in the Room 3D Illustration, Choice Concept

Obesity

Should amylin have been obesity therapeutics’ primary target from the start?

While GLP-1 medicines have become synonymous with weight loss, at least one expert thinks amylin would have been the go-to target if biopharma had been focused on the blockbuster indication 10 years ago. A new wave of therapies is now exploring this potentially gentler mechanism.

October 19, 2026

·

5 min read

·

Heather McKenzie

Glowing neon blue and purple arrows surge upward, representing the high-speed nature of increasing market value in Finance concepts, with business graphic features jagged paths moving upward, illustrating a powerful and increasing growth trajectory.

Drug Development

Veradermics’ minoxidil pill improves hair coverage in men in Phase 3

In the wake of a successful IPO and strong stock growth throughout the year, Veradermics now has late-stage data to support a regulatory package for its hair loss pill.

October 19, 2026

·

3 min read

·

Michael Gibney

Amazing mountain landscape at sunrise, scenic view of silhouettes of the Carpathian mountains range, fantastic colorful sky with clouds and rising sun, outdoor travel background suitable for wallpaper

Rare diseases

Disc’s rebuffed rare disease drug sets up FDA redo after ‘clean’ Phase 3 sweep

Disc Medicine’s bitopertin—rejected by the FDA in February—significantly reduced levels of a key disease biomarker and significantly increased the time patients with erythropoietic protoporphyria were able to spend in the sun and artificial light.

October 19, 2026

·

5 min read

·

Heather McKenzie

Press Releases

NUCLIDIUM and NorthStar Enter Long-term Strategic Partnership to Advance NUCLIDIUM’s Copper-67 Radiotheranostic Oncology Pipeline

October 19, 2026

·

4 min read

Press Releases

Zealand Pharma announces positive topline results from the multiple ascending dose part of Phase 1 trial with Kv1.3 ion channel blocker ZP9830